MX2009012041A - Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa. - Google Patents

Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.

Info

Publication number
MX2009012041A
MX2009012041A MX2009012041A MX2009012041A MX2009012041A MX 2009012041 A MX2009012041 A MX 2009012041A MX 2009012041 A MX2009012041 A MX 2009012041A MX 2009012041 A MX2009012041 A MX 2009012041A MX 2009012041 A MX2009012041 A MX 2009012041A
Authority
MX
Mexico
Prior art keywords
alkyl
dihydroimidazole
hydroxylase
dopamine
inhibitors
Prior art date
Application number
MX2009012041A
Other languages
English (en)
Inventor
David Alexander Learmonth
Alexander Beliaev
Patricio Manuel Vieira Araujo Soares Da Silva
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38198874&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2009012041(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2009012041A publication Critical patent/MX2009012041A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describe el compuesto de la fórmula I y un método para su preparación, en donde R1, R2 y R3 son los mismos o diferentes y significan hidrógenos, halógenos, grupo alquilo, nitro, amino, alquilcarbonilamino, alquilamino o dialquilamino; R4 significa -alquil-arilo o -alquil-heteroarilo; X significa CH2, átomo de oxígeno o átomo de azufre; n es 2 ó 3; incluyendo los enantiómeros (R) y (S) individuales o mezclas de enantiómeros de los mismos; incluyendo sales y ésteres farmacéuticamente aceptables de los mismos. Los compuestos tienen propiedades farmacéuticas potencialmente valiosas para el tratamiento de trastornos cardiovasculares tal como hipertensión y insuficiencia cardiaca crónica.
MX2009012041A 2007-05-08 2008-05-06 Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa. MX2009012041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0708818.0A GB0708818D0 (en) 2007-05-08 2007-05-08 Compounds
PCT/PT2008/000019 WO2008136695A1 (en) 2007-05-08 2008-05-06 1, 3-dihydroimidazole- 2 -thione derivatives as inhibitors of dopamine-beta-hydroxylase

Publications (1)

Publication Number Publication Date
MX2009012041A true MX2009012041A (es) 2010-02-18

Family

ID=38198874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012041A MX2009012041A (es) 2007-05-08 2008-05-06 Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.

Country Status (30)

Country Link
US (5) US8481582B2 (es)
EP (1) EP2155731B1 (es)
JP (1) JP5559677B2 (es)
KR (1) KR101598482B1 (es)
CN (1) CN101687858B (es)
AR (2) AR066457A1 (es)
AT (1) ATE499367T1 (es)
AU (1) AU2008246443B2 (es)
BR (1) BRPI0811275B8 (es)
CA (1) CA2686387C (es)
CL (1) CL2008001321A1 (es)
CY (1) CY1111517T1 (es)
DE (1) DE602008005141D1 (es)
DK (1) DK2155731T3 (es)
ES (1) ES2360841T3 (es)
GB (1) GB0708818D0 (es)
HK (1) HK1142898A1 (es)
HR (1) HRP20110253T1 (es)
IL (1) IL201921A (es)
MX (1) MX2009012041A (es)
NO (1) NO20093275L (es)
NZ (1) NZ580962A (es)
PL (1) PL2155731T3 (es)
RS (1) RS51692B (es)
RU (1) RU2501796C2 (es)
SI (1) SI2155731T1 (es)
TW (1) TWI458722B (es)
UA (1) UA104844C2 (es)
WO (1) WO2008136695A1 (es)
ZA (1) ZA200908612B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
JP6075621B2 (ja) * 2010-08-10 2017-02-08 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
JP6161538B2 (ja) * 2010-12-22 2017-07-12 バイアル−ポルテラ アンド シーエー，エス．エー． 結晶形及びその製造方法
PT2726454T (pt) * 2011-06-29 2018-05-07 Bial Portela & Ca Sa Processo
ES2693025T3 (es) * 2012-11-14 2018-12-07 Bial - Portela & Ca., S.A. Derivados de 1,3-dihidroimidazol-2-tiona para su uso en el tratamiento de hipertensión arterial pulmonar y lesión pulmonar
CN103356671B (zh) * 2013-06-24 2015-11-25 顾祥茂 Houttuynoid C在制备治疗或预防慢性心衰的药物中的应用
GB201316410D0 (en) 2013-09-13 2013-10-30 Bial Portela & Ca Sa Processes for preparing peripherally-selective inhibitors of dopamine-?-hydroxylase and intermediates for use therein
JOP20190049A1 (ar) * 2016-09-23 2019-03-20 Bial Portela & C? S A مثبطات دوبامين-b-هيدروكسيلاز
KR20200054237A (ko) 2017-09-13 2020-05-19 암젠 인크 비스아미드 근육원섬유마디 활성화 화합물 및 이의 용도
SG11202004231YA (en) 2017-12-04 2020-06-29 BIAL PORTELA & Cª S A Dopamine-β-hydroxylase inhibitors
GB201810395D0 (en) * 2018-06-25 2018-08-08 Bial Portela & Ca Sa Formulations comprising dopamine-beta-hydroxylase inhibitors and methods for their preparation
KR20210099010A (ko) * 2018-11-12 2021-08-11 이뮤노젠 아이엔씨 세포독성 벤조디아제핀 유도체의 제조 방법
GB201908044D0 (en) 2019-06-05 2019-07-17 Bial Portela & Ca Sa Dopamine-B-Hydroxylase inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217347A (en) * 1977-12-27 1980-08-12 E. R. Squibb & Sons, Inc. Method of treating hypertension and medicaments therefor
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
ATE243199T1 (de) * 1994-04-26 2003-07-15 Syntex Llc Benzocyclohexylimidazolthion-derivate
AR032711A1 (es) * 2001-02-21 2003-11-19 Solvay Pharm Bv Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
GB2393958A (en) * 2002-10-11 2004-04-14 Portela & Ca Sa Peripherally-selective imidazole inhibitors of dopamine-beta-hydroxylase
US7125904B2 (en) * 2002-10-11 2006-10-24 Portela & C.A., S.A. Peripherally-selective inhibitors of dopamine-β-hydroxylase and method of their preparation
GB0708818D0 (en) 2007-05-08 2007-06-13 Portela & Ca Sa Compounds

Also Published As

Publication number Publication date
SI2155731T1 (sl) 2011-05-31
HK1142898A1 (en) 2010-12-17
TW200918525A (en) 2009-05-01
PL2155731T3 (pl) 2011-07-29
KR20100017546A (ko) 2010-02-16
US9630951B2 (en) 2017-04-25
RU2501796C2 (ru) 2013-12-20
AU2008246443B2 (en) 2013-07-11
CA2686387C (en) 2015-06-30
JP5559677B2 (ja) 2014-07-23
KR101598482B1 (ko) 2016-02-29
CN101687858A (zh) 2010-03-31
CN101687858B (zh) 2012-12-26
US20100137390A1 (en) 2010-06-03
BRPI0811275A2 (pt) 2014-12-23
UA104844C2 (uk) 2014-03-25
TWI458722B (zh) 2014-11-01
IL201921A0 (en) 2010-06-16
BRPI0811275B1 (pt) 2020-01-07
AR112789A2 (es) 2019-12-11
IL201921A (en) 2013-11-28
NZ580962A (en) 2012-05-25
JP2010526136A (ja) 2010-07-29
ZA200908612B (en) 2010-11-24
ES2360841T3 (es) 2011-06-09
US20130345275A1 (en) 2013-12-26
RS51692B (en) 2011-10-31
NO20093275L (no) 2010-02-04
AU2008246443A1 (en) 2008-11-13
DE602008005141D1 (de) 2011-04-07
AR066457A1 (es) 2009-08-19
BRPI0811275B8 (pt) 2021-05-25
DK2155731T3 (da) 2011-05-02
EP2155731A1 (en) 2010-02-24
GB0708818D0 (en) 2007-06-13
US20190322648A1 (en) 2019-10-24
US20170369478A1 (en) 2017-12-28
CA2686387A1 (en) 2008-11-13
RU2009145270A (ru) 2011-06-20
ATE499367T1 (de) 2011-03-15
AU2008246443A8 (en) 2010-01-07
HRP20110253T1 (hr) 2011-05-31
US8481582B2 (en) 2013-07-09
EP2155731B1 (en) 2011-02-23
WO2008136695A1 (en) 2008-11-13
US20210261533A1 (en) 2021-08-26
CL2008001321A1 (es) 2008-12-26
CY1111517T1 (el) 2015-08-05

Similar Documents

Publication Publication Date Title
MX2009012041A (es) Derivados de 1,3-dihidroimidazol-2-tiona como inhibidores de dopamina-beta-hidroxilasa.
MY143578A (en) Piperazinediones as oxytocin receptor antagonists
GEP20125581B (en) Sulfonyl amide derivatives for treatment of abnormal cell growth
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
EA201001669A1 (ru) Замещенные пиримидин-5-карбоксамиды 281
WO2007127635A3 (en) Diketo-piperazine and piperidine derivatives as antiviral agents
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
SE0401971D0 (sv) Piperidne derivatives
HUP0300148A2 (en) Dipeptide nitrile cathepsin k inhibitors, process for their preparation and pharmaceutical compositions containing them
MXPA06009475A (es) Derivados de quinazolina y usos terapeuticos de los mismos.
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
NO20052683L (no) Nye pyridopyrimidinonforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
BR0315580A (pt) Derivados de metileno uréia
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
EP1911757A3 (en) Method of preparation of 3-(1,3-Dihydroimidazole-2-thione-1-yl)-chromanes and thiochromanes as dopamine-beta-hydroxylase inhibitors
WO2008157404A3 (en) Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
MY151072A (en) Heteroaryl derivative
ES2193875A1 (es) Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
SE0401970D0 (sv) Novel compounds
MX2007006744A (es) Derivados de hidantoina utiles como inhibidores de metaloproteinasa.
ATE445396T1 (de) 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i
BRPI0407968A (pt) derivados de oxamida úteis como inibidores de raf-quinase
NO20050903L (no) Nye piperazinyl-pyrazinonderivater for behandling av 5HT-2A reseptorrelaterte forstyrrelser
MX2009013003A (es) Derivados de piperidina-amida.

Legal Events

Date Code Title Description
HH Correction or change in general
FG Grant or registration